Multidrug resistance correlates with unfavourable treatment outcomes in numerous cancers including renal cell carcinoma. The expression and clinical relevance of Glutathione-S-transferase-pi (GST-pi), a multidrug resistance factor, in kidney tumors remain controversial. We analyzed the expression of GST-pi in 60 formalin-fixed, paraffin-embedded renal cell carcinoma samples by immunohistochemistry and compared them with matched normal regions of the kidney. A significantly higher expression of GST-pi was observed in 87% of clear cell carcinoma and 50% of papillary subtypes. GST-pi expression did not correlate with tumor grade or patient survival. GST-pi is unlikely to be a prognostic factor for renal cell carcinoma. However, further studies with large number of samples are warranted to establish the role of GST-pi, if any, in intrinsic or acquired resistance of renal cell carcinoma to conventional treatments.
CITATION STYLE
Kaprilian, C., Horti, M., Kandilaris, K., Skolarikos, A., Trakas, N., Kastriotis, I., & Deliveliotis, C. (2015). Glutathione-S-transferase-pi (GST-pi) expression in renal cell carcinoma. Journal of Kidney Cancer and VHL, 2(1), 25–29. https://doi.org/10.15586/jkcvhl.2015.22
Mendeley helps you to discover research relevant for your work.